C-REACTIVE PROTEIN - THE MOST USEFUL REACTANT OF ACUTE PHASE IN RHEUMATOID ARTHRITIS

  • Dejan Spasovski University Clinic for Rheumatology, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, North Macedonia
  • Emilija Sandevska University Clinic for Rheumatology, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, North Macedonia
  • Ljindita Djemaili Jakupi University Clinic for Rheumatology, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, North Macedonia
  • Ana Vaslievska University Clinic for Rheumatology, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, North Macedonia
  • Svetlana Krstevska Balkanov PHI University Clinic for hematology –Skopje, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, North Macedonia
  • Aleksandra Pivkova Veljanovska PHI University Clinic for hematology –Skopje, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, North Macedonia
  • Maja Jakimovska Institute of Radiology, Faculty of Medicine, Ss.Cyril and Methodius University in Skopje, North Macedonia
  • Vladimir Mitreski PHI Institute of lung disease and tuberculosis, Faculty of Medicine, Ss.Cyril and Methodius University in Skopje, North Macedonia
  • Nikola Chamurovski PHI Institute of lung disease and tuberculosis, Faculty of Medicine, Ss.Cyril and Methodius University in Skopje, North Macedonia
  • Kujtim Iseini PHE Hospital Clinic Tetovo, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, North Macedonia

Abstract

The aim of the study was to determine the most useful biochemical marker of the acute phase
reactants for the evaluation of disease activity in rheumatoid arthritis (RA). Sixty patients with RA were included, 27 of whom were treated with non-steroid anti-inflammatory drugs (NSAIDs) and methotrexate (MTH).
The control group consisted of 33 patients treated only with NSAIDs due to irregular control. In
the first group, disease activity was evaluated at four-week intervals and in the control group at three-
week intervals, following the scores of the articular indices, complete blood count (CBC), elevated
sedimentation rate (ESR), and C-reactive protein (CRP) in every patient. In the first group of patients, decreased activity of RA was found in every subsequent control, with a consecutive decrease in the mean values of the scores of the articular indices and statistically significant differences in the four-time intervals.
Considering laboratory parameters, there were statistically significant differences in the mean
values of haemoglobin (Hb), erythrocytes (Er), platelets (Plt), and ESR (p=0.0462, p=0.0076, p= 0.0058,
p= 0.0003). The mean values of CRP did not show statistically significant differences, but the number of
patients who were CRP negative increased (the standard deviation also increased). In the group of patients
treated only with NSAIDs, there were statistically significant differences in the mean values of the scores
of the articular indices, with increases in every subsequent control (in favor ofdisease progression).
There were no statistically significant differences considering CBC, ESR, and CRP (in favor of a
permanently active disease). CRP is the most useful marker in the prospective evaluation of patients with rheumatoid arthritis.
Keywords: rheumatoid arthritis, articular indices, reactants of the acute phase.


https://doi.org/10.55302/JMS2361068s

References

1. Pincus T, Strand V, Koch G, Amara I, Crawford B, Wolfe F, et al. An index of the three core data set patient questionnaire measures distinguishes efficacy of active treatment from that of placebo as effectively as the American College of Rheumatology 20% response criteria (ACR20) or the Disease Activity Score (DAS) in a rheumatoid arthritis clinical trial. Arthritis Rheum 2003; 48: 625-630.
2. Pincus T, Amara I, Koch GG.Continuous indices of core data set measures in rheumatoid arthritis clinical trials: lower responses to placebo than seen with categorical responses with the American College of Rheumatology 20% criteria. Arthritis Rheum 2005; 52: 1031-1036.
3. Ranganath VK, Elashoff DA, Khanna D, Park G, Peter JB, Paulus HE. Age adjustment corrects for apparent differences in erythrocyte sedimentation rate and C-reactive protein values at the onset of seropositive rheumatoid arthritis in younger and older patients. J Rheumatol 2005; 32: 1040-1042.
4. Balsa A, Carmona L, González-Álvaro I, Belmonte MA, Tina X, Sanmartí R. Value of DAS-28 and DAS 28-3 as compared to ACR-defined remission in rheumatoid arthritis. J Rheumatol 2004;31:40-46.
5. Nell VP, Machold KP, Eberl G, Stamm TA, Uffmann M, Smolen JS. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology 2004; 43: 906-914.
6. Kadir Y, Saliha K, Meltem AM, Gurhan G, Mahir U, Kazim S. Associations between Acute Phase Reactant Levels and Disease Activity Score (DAS28) in Patients with Rheumatoid Arthritis. Annals of Clinical & Laboratory Science 2004;34: 423-426.
7. Matsui T, Kuga Y, Kaneko A, Nishino J, Eto Y, Chiba N, et al. Disease Activity Score 28 (DAS28) using C-reactive protein underestimates disease activity and overestimates EULAR response criteria compared with DAS28 using erythrocyte sedimentation rate in a large observational cohort of rheumatoid arthritis patients in Japan. Ann Rheum Dis 2007 ;66: 1221-1226.
8. Hider SL, Buckley C, Silman AJ, Symmons DP, Bruce IN. Factors influencing response to disease modifying antirheumatic drugs in patients with rheumatoid arthritis. J Rheumatol 2005; 32: 11-16 .
9.Williams AL, O'Sullivan MM, Lewis PA, Coles EC, Jessop JD. Relationship between time-integrated c-reactive protein levels and radiologic progression in patients with rheumatoid arthritis. Arthritis Rheum 2000 ; 43 : 1473-1477.
10.Strand V, Sharp JT Radiographic data from recent randomized controlled trials in rheumatoid arthritis. Arthritis Rheum 2003; 48: 21-34.
11. Michael JP, Arnold LW, O'Sullivan MM, Lewis PA, Coles EC, Jessop JD. Relationship between time- integrated c- reactive protein levels and radiologic progression in patients with rheumatoid arthritis. Arthritis Rheum 2000; 43 : 1473 - 1477.
Published
2023-05-10
How to Cite
SPASOVSKI, Dejan et al. C-REACTIVE PROTEIN - THE MOST USEFUL REACTANT OF ACUTE PHASE IN RHEUMATOID ARTHRITIS. Journal of Morphological Sciences, [S.l.], v. 6, n. 1, p. 68-74, may 2023. ISSN 2545-4706. Available at: <https://jms.mk/jms/article/view/vol6no1-9>. Date accessed: 23 apr. 2024.
Section
Articles